Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs)

McGahan L
Record ID 32018000354
English
Authors' results and conclusions: Overall, ECHELON-2 is the first phase 3, randomised, double-blind, active comparator study to demonstrate that adding Brentuximab vedotin (BV) to CHP increases progression-free survival (PFS), objective response (OR) and complete remission (CR) in previously untreated CD30-positive PTCL patients. While the PFS benefits were generally consistent across subtypes, the study was not powered to compare efficacy between individual histological subtypes and small sample sizes preclude definitively determining the treatment effect in non-systematic ALCL. No clinically meaningful differences were noted in Quality of Life (QoL) measures.
Authors' recommendations: The development of a clinically validated in vitro diagnostic for CD30 expression may ensure the appropriate selection of patients most likely to benefit from BV+CHP therapy. Further studies are needed to better define the efficacy of BV in non-ALCL histologies, optimal dosing to enhance disease control while limiting complications, optimal therapeutic sequence, and use as monotherapy versus in combination with immune checkpoint inhibitors or other immunomodulatory agents.
Details
Project Status: Completed
URL for project: https://aihta.at/page/horizon-scanning-in-der-onkologie/en
Year Published: 2019
URL for published report: http://eprints.aihta.at/1210/1/DSD_HSO_Nr.89.pdf
URL for additional information: http://eprints.aihta.at/1210/
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • Lymphoma, T-Cell
  • Antineoplastic Agents, Immunological
  • Brentuximab Vedotin
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols
  • Immunotoxins
Keywords
  • Peripheral t-cell lymphoma
  • PTCL
  • Brentuximab vedotin
  • antibody-drug conjugate
  • Adcetris®
Contact
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.